2-Bromo-α-ergocryptine methanesulfonate salt
SIGMA/B2134 - solid
Synonym: (+)-2-Bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′-18-trione methanesulfonate salt; (+)-Bromocriptine methanesulfonate salt; Bromocriptine mesylate salt
CAS Number: 22260-51-1
Empirical Formula (Hill Notation): C32H40BrN5O5 · CH4SO3
Molecular Weight: 750.70
EC Number: 244-881-1
MDL Number: MFCD00069218
Linear Formula: C32H40BrN5O5 · CH4SO3
Product Type: Chemical
| color | white |
| form | solid |
| InChI | 1S/C32H40BrN5O5.CH4O3S/c1 |
| InChI key | NOJMTMIRQRDZMT-NEKRQHSLSA |
| optical activity | [α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.) |
| Quality Level | 100 ![]() |
| SMILES string | CS(O)(=O)=O.[H][C@@]12Cc3 |
| solubility | ethanol: 23 mg/mL |
| H2O: 0.8 mg/mL | |
| storage temp. | 2-8°C |
| Application: | 2-Bromo-α-ergocryptine methanesulfonate salt has been used: • as D2 agonist in bird zebra finches • for Prl secretion inhibitor in mice • for the inhibition of motility in planaria worm |
| Biochem/physiol Actions: | Bromocriptine is an ergot alkaloid and a dopamine D2 receptor agonist. It is prescribed for Parkinson′s disorder, hyperprolactinemia and galactorrhoea. It modulates β cells of the pancreas from insulin hypersecretion and improves the metabolic profile in type 2 diabetes patients with obesity. It also modulates glutamate release by glutamate transporter,GLT-1. |
| Symbol | ![]() GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H302 - H410 |
| Precautionary statements | P273 - P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |



